search

Active clinical trials for "Motor Neuron Disease"

Results 21-30 of 760

Open Label Extension of TUDCA-ALS Study

Amyotrophic Lateral Sclerosis

This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.

Recruiting6 enrollment criteria

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

Amyotrophic Lateral Sclerosis

Ambroxol is a simple cough medicine that is predicted to slow ALS disease progression. This study aims to investigate if ambroxol in high doses is effective in treating ALS. This study will be carried out across 5 research sites in Australia (2 NSW, 1 VIC, 1 SA and 1 TAS), where newly diagnosed ALS patients will be asked to participate. Participation will be over a 32-week period, where they will come in for a 4-week screening, 24-week treatment, and 4-week end of study safety follow-up period. The participants will receive either the placebo or drug solution that they will take three times a day, up-dosing each week until they reach the maximum dose or highest dose they can tolerate. Throughout the study their disease progression will be assessed using tests, questionnaires, and blood biomarkers.

Recruiting17 enrollment criteria

Quantitative and Repetitive TMS in ALS

Amyotrophic Lateral Sclerosis

The goal of this open-label pilot clinical trial is to evaluate the safety, tolerability and target engagement of accelerated, high dose continuous theta-burst stimulation (cTBS) using transcranial magnetic stimulation (TMS) in patients with ALS.

Recruiting28 enrollment criteria

Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral...

Amyotrophic Lateral SclerosisALS

The purpose of this pilot study is to assess the safety and tolerability of multiple doses of MaaT033 in ALS patients and to analyze the gut microbiota composition and evolution before considering a larger randomized controlled efficacy study.

Recruiting30 enrollment criteria

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in...

Amyotrophic Lateral Sclerosis

This trial is a Phase 1a/1b, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of prosetin administered to healthy adult subjects.

Recruiting10 enrollment criteria

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

Amyotrophic Lateral Sclerosis (ALS)

The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost approach to significantly slow or stop the progression of ALS, for which currently no effective treatment exists. It is currently thought that oxidative stress is a major cause of ALS. The study investigators are therefore planning to expand the original scope of the previous trial by including anti-oxidants at high doses that were not previously used. All of these compounds are considered safe.

Recruiting9 enrollment criteria

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK)...

Amyotrophic Lateral Sclerosis

The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.

Recruiting20 enrollment criteria

iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

Amyotrophic Lateral Sclerosis

This study consists of a phase 1 part and a phase 2 part. Phase 1 part: This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of bosutinib to determine the maximum tolerated dose(MTD) and a recommended phase 2 dose (RP2D) of bosutinib for treatment of ALS patients. Also, efficacy will be evaluated exploratory. Phase 2 part: This is an open label, multicenter, phase 2 part whose purpose is to evaluate the efficacy exploratorily and the long-term (for 24 weeks) safety of bosutinib for the treatment of ALS patients.

Recruiting106 enrollment criteria

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and...

Amyotrophic Lateral Sclerosis

The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants

Recruiting56 enrollment criteria

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Amyotrophic Lateral Sclerosis

It is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.

Recruiting30 enrollment criteria
1234...76

Need Help? Contact our team!


We'll reach out to this number within 24 hrs